The Ultimate Trial of CTO Recanalization
- PMID: 35863794
- DOI: 10.1016/j.jcin.2022.06.004
The Ultimate Trial of CTO Recanalization
Keywords: CTO; PCI; chronic coronary syndromes; chronic total occlusion.
Conflict of interest statement
Funding Support and Author Disclosures Prof Di Mario has received institutional research grants from AMGEN, Abbott Vascular, Behring, Boston Scientific, Chiesi Pharmaceuticals, Daiichi-Sankyo, Edwards Lifesciences, Medtronic, Shockwave Medical, and Volcano Philips; and he is member and president of the EuroCTO Club, which receives annual grants to support its congress and other activities from Abbott, Asahi Intecc, Biotronik, Boston Scientific, Braun, IMDS, OrbusNeich, Philips Volcano, Shockwave, SISMedical, Teleflex, and Terumo. Dr Ciardetti has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Comparative Analysis of Patient Characteristics in Chronic Total Occlusion Revascularization Studies: Trials vs Real-World Registries.JACC Cardiovasc Interv. 2022 Jul 25;15(14):1441-1449. doi: 10.1016/j.jcin.2022.05.023. JACC Cardiovasc Interv. 2022. PMID: 35863793
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous